BR112023000598A2 - Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia - Google Patents

Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia

Info

Publication number
BR112023000598A2
BR112023000598A2 BR112023000598A BR112023000598A BR112023000598A2 BR 112023000598 A2 BR112023000598 A2 BR 112023000598A2 BR 112023000598 A BR112023000598 A BR 112023000598A BR 112023000598 A BR112023000598 A BR 112023000598A BR 112023000598 A2 BR112023000598 A2 BR 112023000598A2
Authority
BR
Brazil
Prior art keywords
ibuprofen
heartburn
oral
famotidine
severity
Prior art date
Application number
BR112023000598A
Other languages
English (en)
Inventor
Schachtel Bernard
Original Assignee
Schabar Res Associates Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schabar Res Associates Llc filed Critical Schabar Res Associates Llc
Publication of BR112023000598A2 publication Critical patent/BR112023000598A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÕES DE DOSE ORAL UNITÁRIA COMPOSTA DE IBUPROFENO E FAMOTIDINA PARA O TRATAMENTO DA DOR AGUDA E REDUÇÃO DA GRAVIDADE E/OU RISCO DE AZIA. São descritas neste documento composições de dose oral unitária que reduzem a gravidade da azia e/ou o risco de ocorrência de azia em um ser humano que precisa tomar ibuprofeno para o tratamento OTC de dor aguda em que o ser humano não apresenta azia antes da administração oral da composição de dose oral unitária compreendendo a administração oral ao ser humano de uma composição de dose oral unitária compreendendo (i) ibuprofeno em uma dosagem de cerca de 50 mg a cerca de 400 mg por composição de dose oral unitária e (ii) famotidina em uma dosagem de cerca de 3 mg a cerca de 20 mg por composição de dose oral unitária, em que a taxa de dissolução de famotidina na composição de dose oral unitária no referido humano em um tempo especificado dentro de 45 minutos após a administração da referida composição de dose oral unitária ao referido humano é maior do que a taxa de dissolução de ibuprofeno na composição de dose oral unitária no referido humano no mesmo tempo especificado.
BR112023000598A 2020-07-15 2021-07-14 Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia BR112023000598A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063052398P 2020-07-15 2020-07-15
PCT/US2021/041521 WO2022015784A1 (en) 2020-07-15 2021-07-14 Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Publications (1)

Publication Number Publication Date
BR112023000598A2 true BR112023000598A2 (pt) 2023-01-31

Family

ID=77265221

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000598A BR112023000598A2 (pt) 2020-07-15 2021-07-14 Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia

Country Status (11)

Country Link
US (2) US11331307B2 (pt)
EP (1) EP4181912A1 (pt)
JP (1) JP2023534810A (pt)
KR (1) KR20230051164A (pt)
CN (1) CN116194102A (pt)
AU (1) AU2021310264A1 (pt)
BR (1) BR112023000598A2 (pt)
CA (1) CA3159988C (pt)
CO (1) CO2023000516A2 (pt)
IL (1) IL299845A (pt)
WO (1) WO2022015784A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534810A (ja) * 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102902A (en) 1973-06-18 1992-04-07 Mercer James B Reagents and method for therapeutic treatment of multiple sclerosis
US4279906A (en) 1977-11-10 1981-07-21 Nasa Indomethacin-antihistamine combination for gastric ulceration control
US4230717A (en) 1978-12-29 1980-10-28 Lovelace Alan M Administrator Indomethacin-antihistamine combination for gastric ulceration control
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
JPS57209968A (en) 1981-06-19 1982-12-23 Kanegafuchi Chem Ind Co Ltd Coated material having metallic finish
US4794112A (en) 1982-12-09 1988-12-27 Cooper Stephen A Acetaminophen/hydroxyzine analgesic combinations
US4599359A (en) 1982-12-09 1986-07-08 Stephen A. Cooper Hydroxyzine-containing analgesic combinations
US4567183A (en) 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4755532A (en) 1984-02-08 1988-07-05 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4683243A (en) 1984-02-08 1987-07-28 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4871733A (en) 1984-04-09 1989-10-03 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4757060A (en) 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
US5037815A (en) 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
HU196775B (en) 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
US4975426A (en) 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US5009875A (en) 1988-08-03 1991-04-23 International Dioxcide, Inc. Process of preparing clorine dioxide and apparatus therefor
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
NZ235877A (en) 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
WO1992005783A1 (en) 1990-09-28 1992-04-16 Merck & Co., Inc. Ibuprofen-antihistamine combinations
US5362737A (en) 1991-04-09 1994-11-08 Chemex Pharmaceuticals, Inc. Methods of treating aphthous ulcers and other mucocutaneous disorders with amlexanox
EP0558876A1 (en) 1992-03-03 1993-09-08 STMicroelectronics S.r.l. A semiconductor device package with shaped parts for direct coupling to standard connectors
US5229137A (en) 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
US6303632B1 (en) 1992-09-03 2001-10-16 Sepracor Inc. Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients
DE69327328T2 (de) 1992-09-03 2000-06-21 Sepracor Inc Verwendund von norastemizol zur behandlung der allergischen rhinitis
JPH08502254A (ja) 1992-09-29 1996-03-12 メルク エンド カンパニー インコーポレーテッド イブプロフェン−ｈ▲下２▼拮抗薬配合物
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
AU7973994A (en) 1993-10-13 1995-05-04 Merck & Co., Inc. Combination therapy for hiv infection
US5541212A (en) 1994-01-10 1996-07-30 Metatron, Inc. Use of cimetidine for the control of retrovirus infections
US5763422A (en) 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
EP0725553B1 (en) 1995-02-06 2005-09-21 Alcatel Cell switching network
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5955451A (en) 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
TW469135B (en) 1995-10-03 2001-12-21 Chugai Pharmaceutical Co Ltd Chewable tablet
EP0790003B1 (en) 1996-02-15 2003-01-15 Puratos N.V. Process for obtaining improved structure build-up of baked products
GB2318511A (en) 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
US6160020A (en) 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
US6027746A (en) 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
WO1998053802A1 (en) 1997-05-30 1998-12-03 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US5993327A (en) 1998-05-19 1999-11-30 Terry Terril Golf putting device and method of using the same to putt a golf ball
US6071523A (en) 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
GB2338896B (en) 1998-07-02 2003-05-21 Reckitt & Colmann Prod Ltd Chewable Capsules
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
EA004032B1 (ru) 1998-09-10 2003-12-25 Нюкомед Данмарк А/С Фармацевтические композиции лекарственных веществ с быстрым высвобождением
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
AU772188B2 (en) 1998-11-17 2004-04-08 Nitromed, Inc. Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
GB9910212D0 (en) 1999-05-05 1999-06-30 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
IT1314184B1 (it) 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
DK1276470T3 (da) 2000-04-20 2007-06-18 Novartis Ag Smagskaskerende overtrækssammensætning
US7678387B2 (en) 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US6417184B1 (en) 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
EP2260837A1 (en) 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6767200B2 (en) 2001-09-28 2004-07-27 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
BR0212950A (pt) 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas tendo uma porção inserida
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
EP1471872A2 (en) 2002-02-04 2004-11-03 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
JP2005531520A (ja) 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
AU2003223631B2 (en) 2002-04-18 2006-07-20 Schering Corporation 1-(4-Piperidinyl) benzimidazolones as histamine H3 antagonists
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
CN100497334C (zh) 2002-06-24 2009-06-10 先灵公司 用作组胺h3拮抗剂的吲哚衍生物
AU2004238321B2 (en) 2003-05-07 2009-08-27 Samyang Biopharmaceuticals Corporation Highly plastic granules for making fast melting tablets
CA2791779A1 (en) 2003-10-28 2005-05-12 Taro Pharmaceuticals U.S.A., Inc. Spill resistant formulations containing clays
US20060034943A1 (en) 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
US20050095197A1 (en) 2003-10-31 2005-05-05 Tuszynski Jack A. Anti-mitotic compound
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
WO2005063219A2 (en) 2003-12-23 2005-07-14 Ranbaxy Laboratories Limited Ibuprofen-containing soft gelatin capsules
US20050163847A1 (en) 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
WO2006052856A1 (en) 2004-11-04 2006-05-18 Reliant Pharmaceuticals, Inc. System and method of treatment with nizatidine
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US20070043097A1 (en) 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20080085314A1 (en) 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007054480A1 (en) 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
WO2007072503A2 (en) 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
US20070154542A1 (en) 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
WO2007082206A2 (en) 2006-01-10 2007-07-19 Yu Ruey J N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
US20070202058A1 (en) * 2006-02-27 2007-08-30 Calwood Nutritionals, Inc. Compositions for treating gastric reflux
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
WO2008011426A2 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
EP2063873A2 (en) 2006-08-31 2009-06-03 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
CA2918576C (en) 2006-10-09 2019-01-08 Paul Bosse Immediate release analgesic and antiemetic combination compositions
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
WO2009089134A1 (en) 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US20090233970A1 (en) 2008-03-11 2009-09-17 Nickell Robert P Combined nsaid and acid blocker formulation and method
US20090275622A1 (en) 2008-04-30 2009-11-05 Prasoona Linga Nizatidine formulations
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
US11931444B2 (en) 2018-03-20 2024-03-19 Dsm Ip Assets B.V. Topical composition
JP2023534810A (ja) * 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Also Published As

Publication number Publication date
US20220016088A1 (en) 2022-01-20
CN116194102A (zh) 2023-05-30
US20220233510A1 (en) 2022-07-28
AU2021310264A1 (en) 2023-02-09
IL299845A (en) 2023-03-01
EP4181912A1 (en) 2023-05-24
WO2022015784A1 (en) 2022-01-20
CA3159988A1 (en) 2022-01-20
CA3159988C (en) 2023-09-19
KR20230051164A (ko) 2023-04-17
US11331307B2 (en) 2022-05-17
JP2023534810A (ja) 2023-08-14
CO2023000516A2 (es) 2023-01-26

Similar Documents

Publication Publication Date Title
Usha et al. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis
Sanz-Paris et al. Role of Oral Nutritional supplements enriched with b-hydroxy-b-methylbutyrate in maintaining muscle function and improving clinical outcomes in various clinical settings
Sortino et al. Strategies used to inhibit postoperative swelling following removal of impacted lower third molar
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR112023000598A2 (pt) Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia
BR0008847A (pt) Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
Lin et al. Etodolac versus dexamethasone effect in reduction of postoperative symptoms following surgical endodontic treatment: a double-blind study
BR0008060A (pt) Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
JP2008509224A5 (pt)
BR0006024A (pt) Composição para o tratamento de inflamação e dor em mamìferos
Razmara et al. An investigation into the prevalence and treatment of oral mucositis after cancer treatment
US20190374491A1 (en) Topical preparation for pain relief
JP2020500864A5 (pt)
Isler et al. Oral flurbiprofen spray for mucosal graft harvesting at the palatal area: A randomized placebo‐controlled study
KR970061244A (ko) 치매 치료용 약학 조성물
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
US20200038341A1 (en) Methods and compositions for treating joint disease
BRPI0519036A2 (pt) mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
Bhoobalakrishnan et al. Comparison of efficacy and safety of bromelain with diclofenac sodium in the management of postoperative pain and swelling following mandibular third molar surgery
WO2012059874A1 (en) A mouthwash composition for managing oral mucositis, process and methods thereof
BR112022008095A2 (pt) Métodos e composições para o tratamento da síndrome de rett
Kuvayev et al. Experimental and clinical substantiation nof nitric oxide metabolism correction in the complex therapy of patients with generalized periodontitis
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
Yang et al. Sodium Hyaluronate Combined with Jintiange on Knee Joint Function After Arthroscopy for Knee Osteoarthritis